Compare FUSB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUSB | ONCY |
|---|---|---|
| Founded | 1952 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8M | 94.0M |
| IPO Year | N/A | 1999 |
| Metric | FUSB | ONCY |
|---|---|---|
| Price | $15.03 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.0K | ★ 1.9M |
| Earning Date | 01-28-2026 | 03-06-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $37,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.30 | $0.33 |
| 52 Week High | $15.99 | $1.51 |
| Indicator | FUSB | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 36.51 |
| Support Level | N/A | $0.81 |
| Resistance Level | N/A | $1.06 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 2.88 |
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.